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Abstract
Background: Juvenile Idiopathic Arthritis (JIA) may cause significant impairment in health-related quality of life
(HrQoL), despite effective therapies. The aim of this study was to assess HrQoL during first-year treatment in
patients with new-onset polyarticular JIA, and to compare treatment strategies.
Methods: In ACUTE-JIA Study, 60 patients with new-onset JIA were randomized to receive either infliximab with
methotrexate (IFX+MTX); a triple therapy of methotrexate, hydroxychloroquine, and sulfasalazine (Triple); or
methotrexate monotherapy (MTX). Efficacy was measured with American College of Rheumatology pediatric (ACRp)
score, and juvenile arthritis disease activity score (JADAS). HrQoL was evaluated with Child Health Questionnaire
(CHQ), which includes physical and psychosocial summary scores (PhS and PsS). Linear mixed models were utilized
to compare groups over time.
Results: In the whole group of 60 patients, mean physical summary score (PhS) improved from 26.2 (SD 8.7) at
week 0 to 49.7 (SD 13.2) at week 54 (p=0.046). Mean improvement of PhS was 20.3 (95% CI -15.5 to 56.2); 22.6
(-19.5 to 64.7); and 26.6 (-12.1 to 65.3) in IFX+MTX, Triple, and MTX, respectively. Changes in psychosocial summary
score (PsS) were smaller: from 51.0 (SD 8.5) to 54.7 (6.3) (p=0.019) in all patients. No differences between the three
treatment groups were detected in either of the measures. In multivariate analyses, Child Health Assessment
Questionnaire (CHAQ), pain VAS, and time spent in inactive disease contributed to improvement in PhS; gender
and CHAQ to PsS.
Conclusions: HrQol improved during the first year on therapy for JIA irrespective of the treatment strategy. The
timing of change in the different dimensions of HrQoL varied; improvement occurred earlier in physical than
psychosocial domains of HrQol.
Trial registration: This study was registered within the Hospital District of Helsinki and Uusimaa (http://www.hus.fi)
clinical trials, number 211864 in October 2002, and later on with ClinicalTrials.gov, number NCT01015547.
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Background
Juvenile idiopathic arthritis (JIA) is a chronic condition,
which may cause disability and functional impairment.
JIA is treated with non-steroidal anti-inflammatory
drugs, synthetic disease-modifying anti-rheumatic drugs
(DMARDs), glucocorticoid injections, and in refractory
disease, with biologic drugs.
Health-related Quality of Life (HrQoL) is a multi-
dimensional health outcome concept, which takes into
account perspectives of well-being, physical health, and
psychological state, as well as the surrounding culture
and environment [1]. In health technology assessments
of new treatment approaches, HrQoL is an important
component in the measurement of efficacy. In JIA, base-
line HrQoL seems to have an independent role in pre-
dicting disease activity and functional disability [2].
Patients with JIA often have impaired HrQoL [3]. On
the other hand, effective therapies targeting disease ac-
tivity have improved HrQoL [4]. Besides disease activity,
other factors such as pain, disability, and burden of
medication can affect HrQoL [5].
In patients with new-onset JIA, only a few studies have
evaluated the effects of treatment on HrQoL. In a recent
german inception cohort, psychosocial health reached
the level of normal population at 18 months from onset,
whereas a significant difference in physical health
remained [4]. Disease activity, functional disability [4, 6],
parent or patient global assessment of wellbeing, and
pain [4] seem to play a major role in HrQoL. Yet it is
not known how safety and efficacy of different medica-
tions affect HrQoL.
In this study, we aimed to assess HrQoL during the
first-year of early aggressive treatment in patients with
polyarticular JIA, and the impact of different treatments
on HrQoL.
Methods
This study was part of the ACUTE-JIA Study, in which
sixty patients with new-onset polyarticular JIA were ran-
domized into three treatment arms: infliximab with
methotrexate (IFX+MTX); a combination of methotrex-
ate, hydroxychloroquine, and sulphasalazine (Triple), or
methotrexate monotherapy (MTX). Study protocol has
been described in detail previously [7]. In brief, patients
entered the trial very early in the disease course, less
than 6 months from disease onset. During the first year,
patients underwent altogether eight study visits. During
the first year, patients underwent altogether eight study
visits. At these visits, disease activity was measured with
American College of Rheumatology pediatric (ACRp)
scores, and juvenile arthritis activity score (JADAS).
Medication was adjusted according to the study proto-
col, aiming to a minimum of ACRp 30 improvement. At
seven visits (weeks 0, 6, 12, 24, 36, 48, and 54) HrQoL
was measured with parents’ proxy reports on Child
Health Questionnaire (CHQ)-PF50. Pain was measured
on a visual analog scale (0-100 mm). The preliminary
Wallace criteria [8] were used to define clinically inactive
disease (CID). Intra articular corticosteroids (GCs) were
allowed as symptomatic treatment, whereas systemic
GCs were not allowed.
CHQ is an international, validated, and generic HrQoL
survey. CHQ-PF50 has 50 questions that together pro-
duce 15 health concepts (Global Health, Physical Func-
tioning, Role/Social Limitations - Emotional/Behavioral
or Physical, Bodily Pain/Discomfort, Behavior, Global
Behavior Item, Mental Health, Self Esteem, General
Health Perceptions, Change in Health, Parental Impact
-Emotional or Time, Family Activities and Cohesion),
each producing values between 0-100. It also constitutes
two summary scores Physical Summary Score (PhS), and
Psychosocial Summary Score (PsS), which have been
standardized with a linear T-score transformation (mean
50; one standard deviation of age and sex matched
healthy children is 10, changes of 5 or 8 are considered
moderate or large). In a normal U.S. population sample,
mean PhS is 53.0 (SD 8.8), and PsS 51.2 (SD 9.1) Higher
scores indicate for better health [9].
The CHQ values were calculated as advised by the
publisher [9]. For missing items, scores were imputed if
at least half of the items in the scale were completed, as
advised. For patients who discontinued medication, the
last observation on intended treatment was carried
forward.
Statistical analyses
Differences between groups at baseline were tested with
one-way analysis of variance, Kruskal-Wallis test, or Chi
square, as appropriate. Paired samples t-test was used to
test differences in summary scores between time points.
A linear mixed model was developed to investigate
changes in summary scores over time, and contributing
factors. First, demographic and variables related to treat-
ment and disease activity were selected to perform sep-
arate univariate analyses. Second, significant variables
were used in the final linear mixed model.
IBM SPSS Statistics Version 24 (IBM Corp., Armonk,
NY, USA) was used for all statistical analyses.
Results
Parents of all 60 patients filled the CHQ in the begin-
ning of the study. Of these, 20 patients remained on
intended treatment on IFX+MTX, 16 on Triple, and 11
on MTX. Patients in IFX+MTX achieved and remained
in inactive disease more often than in other groups. Dif-
ferences between Triple and MTX were not statistically
significant (7). Patients in MTX had more infections and
transient elevations of liver enzymes than in other
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groups. Nausea was more common in Triple. 3 patients
in Triple and 8 in MTX discontinued due to inefficacy,
one patient in Triple and one in MTX due to an adverse
event. At baseline, compared with other treatment
groups, patients on IFX+MTX had lower CHAQ,
JADAS, and pain. PhS and PsS levels were similar in all
treatment groups. (Table 1)
Mean (SD) PhS at week 54 was 49.9 (15.5) on
IFX+MTX; 49.9 (12.0) on Triple; and 49.3 (12.9) on
MTX, (p=0.98). Changes in PhS in the total cohort were
significant between weeks 0 to 6 (p= 0.023); 6 to 12 (p=
0.020); and 12 and 24 (p=0.004) (Figure 1). Mean PsS at
week 54 was 54.9 (6.0) on IFX+MTX; 55.0 (6.8) on
Triple; and 54.1 (6.3) on MTX, (p=0.89). There were no
significant changes between consecutive weeks, but
scores at weeks 24, 36, 48, and 54 were significantly
higher than at week 0. (Fig. 1a and b)
In the mixed model, Child Health Assessment Ques-
tionnaire (CHAQ), pain, and cumulative time spent in
CID prior to each study visit contributed significantly to
PhS values (Table 2). For PsS, gender and CHAQ
remained significant contributors in the mixed model
(Table 3).
Of the single domains of HrQoL; bodily pain (BP), role
or social limitations due to physical reasons (RP), phys-
ical functioning (PF), global health perception (GH), and
parental emotional impact (PE) differed from normal
population at week 0. Other domains did not differ from
normal population. At week 54, patients reached normal
population in other domains, except GH (Fig. 1c)
Discussion
In the present intention-to-treat analysis of new-onset
polyarticular JIA, HrQoL improved irrespective of the
treatment strategy, although the timing of change in the
dimensions of HrQoL varied. This suggests that early ag-
gressive treatment of JIA either with biologics or syn-
thetic DMARDs makes it possible to control imminent
impairment of HrQoL.
Table 1 Baseline characteristics of 60 patients with new-onset
polyarticular JIA
IFX+ MTX Triple MTX p
Age (yrs) 10.5
(4.5—14.9)
8.2
(4.8—13.3)
10.1
(4.0—14.4)
0.06
Female (%) 14 (70) 14 (70) 11 (55) 0.21
Time (months) from
disease onset
0.82
(0.0-2.7)
1.77
(0.03—7.0)
1.18
(0.03—7.1)
0.20
Rheumatoid factor
positive
0 1 (5) 0
JIA subtype
Polyarthritis,
seronegative
19 (95) 16 (80) 15 (75)
Enthesitis-related
arthritis (%)
1 (5) 3 (15) 4 (20)
Polyarthritis,
seropositive
0 1 (5) 0
Psoriatic arthritis 0 0 1 (5)
CHAQ 0.49
(0—1.75)
0.71
(0—2.00)
1.07
(0—1.88)
0.01
JADAS10 17.1
(6.9—23.4)
20.1
(9.8—29.8)
21.9
(11.4—30.6)
0.01
Pain-VAS 24.5
(0—90)
37.6
(4—78)
46.7
(2—85)
0.02
PhS 28.2
(21.4—35.1)
28.8
(17.9—39.6)
21.9
(12.8—30.9)
0.46
PsS 51.4
(27.1—58.5)
48.9
(37.1—62.8)
52.8
(40.2—65.8)
0.28
Values are presented as mean (range), unless otherwise stated. IFX+MTX:
infliximab+methrotrexate; Triple: Triple therapy of sulphasalazine,
hydroxychloroquine, and methotrexate; MTX: methotrexate; CHAQ child health
assessment questionnaire, JADAS juvenile arthritis disease activity score, VAS
visual analoque scale, PhS Physical summary Score, PsS Psychosocial
summary Score
Fig. 1 Evolution of health-related quality of life during first year in patients with JIA
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Table 2 Factors contributing to Physical Summary Score (PhS) in
60 patients with new-onset polyarticular juvenile idiopathic arthritis
Univariate Mixed Model
β (95% CI)/
Mean PhS (95% CI)
p β (95% CI) p
Gender
(mean)
0.14
Female 44.5 (40.7 to 48.3)
Male 39.9 (34.9 to 44.8)
Time of visit
(weeks)a
<0.001 <0.001
0 26.22
(22.04 to 30.39)
35.46
(30.91 to 40.04)
6 33.53
(29.43 to 37.63)
38.38
(34.30 to 42.46)
12 38.69
(34.59 to 42.79)
39.95
(36.34 to 43.55)
24 47.98
(43.76 to 52.19)
43.57
(41.63 to 45.86)
36 48.07
(43.81 to 52.32)
44.62
(42.04 to 47.19)
48 49.80
(45.54 to 54.05)
44.29
(41.07 to 47.51)
54 51.66
(47.40 to 55.91)
46.51
(43.66 to 49.35)
Age at onset -0.01 (-0.97 to 0.95) 0.98
Treatment
(mean) b
0.043 0.419
IFX+ MTX 46.2 (41.0 to 50.5) 0.046c 40.19
(36.98 to 43.42)
Triple 45.5 (40.4 to 50.5) 0.065d 42.70
(39.85 to 45.55)
MTX 38.7 (33.5 to 43.9) 42.65
(39.53 to 45.78)
JADAS10 -1.258
(-1.45 to -1.06)
<0.001 -0.347
(-0.72 to 0.024)
0.067
Pain-VAS -0.432
(-0.49 to -0.38)
<0.001 -0.204
(-0.28 to -0.12)
<0.001
Corticosteroid
usee
-0.473
(-0.64 to -0.30)
<0.001 -0.004
(-0.019 to 0.10)
0.554
Time in
remissionf
0.204
(0.073 to 0.334)
0.003 0.172 (0.05 to 0.29) 0.005
CHAQ -23.25
(-26.1 to -20.4)
<0.001 -11.2
(-15.8 to -6.67)
<0.001
CHAQ*JADAS 0.087 (-0.29 to 0.47) 0.658
For numerical factors, Coefficient beta indicated; for categorical values
mean PhS value indicated.
Sidak correction for multiple comparisons used. Factors with p-value <0.05
in univariate analyses were selected for multivariate mixed model. Values
shown in Mixed Model column have been adjusted with other variables in
the model. IFX+MTX: infliximab plus methotrexate; Triple: methotrexate,
hydroxychloroquine, and sulfasalazine; MTX methotrexate monotherapy,
JADAS juvenile arthritis disease activity score, VAS visual analoque scale,
CHAQ child health assessment questionnaire, PhS Physical summary Score.
aValues present mean (95% CI) PhS in all patients at each time point
bValues present mean (95%CI) PhS at all time points in each treatment
group cIFX+MTX vs MTX; dTriple vs MTX; for IFX+MTX vs Triple p=0.84;
eAmount of corticosteroids per body weight (intra-articular or oral) before
individual study visit, adjusted for 6 weeks’ time (mg/kg); fCumulative time in
remission since onset, *interaction term
Table 3 Factors contributing to Psychosocial Summary Score
(PsS) in 60 patients with new-onset polyarticular juvenile
idiopathic arthritis
Univariate Mixed Model
β (95% CI)/
Mean PsS (95% CI)
p β (95% CI) p
Gender (mean) <0.001
Female 54.66
(53.78 to 55.54)
Male 51.12
(49.98 to 53.27)
Time of visit
(weeks)
0.036
0 51.00
(49.10 to 52.90)
6 52.02
(50.15 to 53.89)
12 52.76
(50.89 to 54.63)
24 53.81
(51.94 to 55.68)
36 54.48
(52.58 to 56.38)
48 54.70
(52.82 to 56.58)
54 54.66
(52.77 to 56.54)
Age at onset 0.134 (-0.92 to 0.36) 0.245
Treatment
(mean)
0.113
IFX+ MTX 53.72 (52.4 to 55.0) 0.971a
Triple 52.4 (51.1 to 53.5) 0.139b
MTX 54.1 (52.8 to 55.3)
JADAS10 -0.251
(-0.378 to -0.125)
<0.001 -0.038
(-0.24 to 0.16)
0.701
Pain-VAS -0.084
(-0.118 to -0.051)
<0.001 0.001
(-0.055 to 0.58)
0.96
Corticosteroid
used
-0.005
(-0.014 to 0.003)
0.193
Time in
remissione
0.009
(-0.035 to 0.054)
0.679
CHAQ -5.710
(-7.117 to -4.303)
<0.001 -5.07
(-7.85 to -2.29)
<0.001
CHAQ*JADAS -0.116
(-0.309 to 0.077)
0.237
CHAQ*Pain-VAS 0.047
(-0.011 to 0.105)
0.115
For numerical factors, Coefficient beta indicated; for categorical values
mean PsS value indicated.
Sidak correction for multiple comparisons used. Factors with p-value <0.05
in univariate analyses were selected for multivariate mixed model. Values
shown in Mixed Model column have been adjusted with other variables in
the model. IFX+MTX: infliximab plus methotrexate; Triple: methotrexate,
hydroxychloroquine, and sulfasalazine; MTX methotrexate monotherapy,
JADAS juvenile arthritis disease activity score, VAS visual analoque scale, CHAQ
child health assessment questionnaire, PsS Psychosocial summary Score.
aIFX+MTX vs MTX; bTriple vs MTX; for IFX+MTX vs Triple p=0.318; dAmount of
corticosteroids per body weight (intra-articular or oral) before individual study
visit, adjusted for 6 weeks’ time (mg/kg); eCumulative time in remission since
onset, *interaction term
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Physical condition improved soon after the onset of
aggressive therapy, simultaneously with the decrease in
disease activity. In a recent study from Canada, improve-
ment in HrQoL occurred later than in other disease out-
come measures, several years after improvement of
disease activity [5]. However, in that study only 10% of
patients received biologics. In the current study, each of
CHAQ, pain VAS, and time spent in CID were associ-
ated with improvement in physical condition. This un-
derlines the significance of controlling disease activity to
ensure good quality of life.
The changes of psychosocial condition in this study
were minor, and significant improvement over time
compared to the situation at onset of therapy could not
be seen until week 24. Usually, psycho-social compo-
nents of QoL have been affected to lesser extent than
physical components [3, 4]. In line with the present
study, previous studies utilizing CHQ or SF-36 have
found only small changes in PsS [10]. In a recent study
on abatacept, measured with CHQ, patients with JIA re-
ported better PsS values than healthy normal population,
already in the beginning of treatment [11].
In this study, the subdomain parental emotional im-
pact remained below normal population at the end of
the first year. Measurements in this study were parent
proxy-reports, which however have shown similarities
[12] with the juvenile patients’ self-reporting. In a previ-
ous study on patients with new-onset polyarticular JIA,
parental emotional scores have been a significant pre-
dictor of proxy-reported HrQoL [4]. These findings indi-
cate that it is important to pay attention to parents’
emotions to enable holistic approach for patient care
in JIA.
In this study, pain contributed to physical aspects of
QoL. This was also demonstrated previously [3, 4, 13].
This suggests that instead of HrQoL questionnaires with
multiple items, pain VAS could possibly be used in clin-
ical work as a rapid tool to assess patient’s well-being.
In long-term follow-up studies, patients with JIA have
shown poorer HrQoL than their peers, even despite their
low disease activity [6, 10]. One reason for this might be
the less effective treatment available at the time of dis-
ease onset of these studies. The current study demon-
strated that despite the differences in the safety and
efficacy profiles of biologics and DMARDs [14, 15], these
treatments are equal in improving HrQoL, when used in
a treat-to-target manner.
A limitation of this study was the small sample size,
which decreased the power to detect differences between
treatment groups. Despite the fact that there were differ-
ences in the efficacy (IFX +MTX was more effective than
other treatments), no differences were detected in the
evolution of HrQoL. This might be due to the small
sample size, and the differences at baseline. HrQoL was
measured during the first year from disease onset. Lon-
ger follow-up time may be needed to reveal the effects
of early aggressive therapy and other contributing factors
on HrQoL. The effects of non-medical conditions, such
as social support and school absence, were not
measured.
To the best of our knowledge, this is the first study
comparing HrQoL between biologic and synthetic
DMARD therapy. In the future, a long-term follow-up
study on HrQoL, assessing the effects of early aggressive
treatment and factors associated with HrQoL might dir-
ect treatment decisions towards better patient-reported
outcomes.
Conclusions
In conclusion, quality of life improved in all treatment
groups during the first year from onset of polyarticular
JIA. Despite their different efficacy and safety profiles,
infliximab and synthetic DMARDs, when used early and
aggressively, were effective in improving health-related
quality of life.
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